Zapping resistant tumors to keep lung cancer at bay

This study is testing if adding a precise, high-dose radiation treatment to a standard targeted drug can help people with advanced lung cancer live longer without their cancer getting worse. It focuses on patients whose cancer has a specific genetic change (EGFR mutation) and who are already taking the drug osimertinib. The idea is to use radiation to destroy small areas of cancer that might be less sensitive to the drug alone, aiming to delay the cancer's return.